Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment.
COVID-19
coinfection
cutaneous leishmaniasis
prophylactic effect
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
14
05
2021
revised:
18
09
2021
accepted:
21
09
2021
pubmed:
28
9
2021
medline:
9
9
2022
entrez:
27
9
2021
Statut:
ppublish
Résumé
We assessed the potential relationship between COVID-19 and laboratory-confirmed cutaneous leishmaniasis (CL)-registered cases with a history of scarring, compared with volunteer participants without history of CL. This case-control retrospective study was conducted in southeastern Iran with a high anthroponotic cutaneous leishmaniasis (ACL) burden. Overall, n=1010 CL cases (n=479 male, n=531 female) were evaluated for infection with SARS-CoV-2. In the CL case group, 2 men and 1 woman (0.3% in total) had a mild form of COVID-19 disease; none were hospitalized or died. In contrast, of n=2020 participants without history of CL, n=57 (2.9%) contracted laboratory-confirmed COVID-19, including mild (66.7%), hospitalized (26.3%), critical (3.5%) and fatal (3.5%). There was a strong negative association between CL infection and COVID-19. The burden of COVID-19 in CL-cured participants significantly reduced the morbidity (odds ratio: 0.12; CI: 0.03-0.30; P <0.001) and mortality (percentile: -4.10, -0.02). Participants with a history of CL scar had significantly reduced incidence of COVID-19 morbidity and mortality. The cross-protection mediated by CL may retard COVID-19 in endemic countries. However, further longitudinal studies are needed to explore the potential profile and duration of this protection offered by CL against COVID-19.
Identifiants
pubmed: 34571149
pii: S1201-9712(21)00757-8
doi: 10.1016/j.ijid.2021.09.050
pmc: PMC8461267
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
155-161Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
BMJ. 2003 Feb 15;326(7385):377-82
pubmed: 12586674
J Immunol. 2010 Jan 15;184(2):886-94
pubmed: 19966209
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
J Innate Immun. 2014;6(2):152-8
pubmed: 24192057
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17720-17726
pubmed: 32647056
Parasitology. 2001;122 Suppl:S23-38
pubmed: 11442193
Front Cell Infect Microbiol. 2020 Aug 18;10:425
pubmed: 32974217
Clin Ther. 2013 Feb;35(2):109-14
pubmed: 23375475
Vaccine. 2020 Jul 31;38(35):5582-5590
pubmed: 32616328
Front Immunol. 2020 Aug 07;11:1573
pubmed: 32849534
Bull Soc Pathol Exot Filiales. 1983 Aug-Oct;76(4):377-83
pubmed: 6354498
PLoS One. 2018 Feb 7;13(2):e0192236
pubmed: 29415078
Indian J Tuberc. 2021 Jan;68(1):119-124
pubmed: 33641831
Infect Dis Poverty. 2019 Jun 15;8(1):49
pubmed: 31200765
Microb Pathog. 2019 Mar;128:162-170
pubmed: 30583021
Infect Immun. 1993 Sep;61(9):4008-12
pubmed: 8359927
PLoS Negl Trop Dis. 2016 Mar 03;10(3):e0004349
pubmed: 26937644
New Microbes New Infect. 2020 Nov;38:100817
pubmed: 33230417
Vaccine. 2005 May 25;23(28):3642-8
pubmed: 15882524
PLoS Negl Trop Dis. 2017 Aug 10;11(8):e0005739
pubmed: 28796782
Clin Microbiol Infect. 2019 Dec;25(12):1473-1478
pubmed: 31055165
Int Immunopharmacol. 2019 Apr;69:321-327
pubmed: 30771740
Lancet. 2020 May 16;395(10236):1545-1546
pubmed: 32359402
Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5
pubmed: 29324233
Microb Pathog. 2018 Mar;116:124-129
pubmed: 29353004
J Exp Med. 2001 Nov 19;194(10):1497-506
pubmed: 11714756
Proc Biol Sci. 2014 Mar 11;281(1782):20132286
pubmed: 24619434
Iran J Public Health. 2015 Mar;44(3):299-307
pubmed: 25905072
Indian J Clin Biochem. 2020 Jul;35(3):260-273
pubmed: 32641873
Parasitology. 1989;98 Suppl:S49-60
pubmed: 2657601
East Mediterr Health J. 2015 Jun 09;21(4):280-6
pubmed: 26077523
IUBMB Life. 2019 Nov;71(11):1685-1700
pubmed: 31329370
Vaccine. 2008 Jan 10;26(2):269-76
pubmed: 18037544
Immunobiology. 2008;213(3-4):377-87
pubmed: 18406382
PLoS One. 2012;7(5):e35671
pubmed: 22693548
PLoS Negl Trop Dis. 2019 Feb 25;13(2):e0007092
pubmed: 30802261
Life Sci. 2020 Sep 15;257:118102
pubmed: 32687918
Viral Immunol. 2017 Jul/Aug;30(6):421-430
pubmed: 28650258
Nat Rev Immunol. 2016 Sep;16(9):581-92
pubmed: 27424773
PLoS Negl Trop Dis. 2016 May 26;10(5):e0004545
pubmed: 27227772
PLoS Negl Trop Dis. 2019 Jun 12;13(6):e0007423
pubmed: 31188834
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
Hum Vaccin Immunother. 2020 Dec 1;16(12):2954-2962
pubmed: 32991235
J Immunol. 2000 Feb 1;164(3):1458-62
pubmed: 10640762
Infect Dis Poverty. 2020 Apr 28;9(1):45
pubmed: 32345362
Viral Immunol. 2021 Jun;34(5):307-320
pubmed: 33147113